Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Go back to Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026| (NASDAQ: TNYA) | Delayed: 0.73 +0.02 (2.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.71 | 52 Week High | $ | |||
| Open | $0.71 | 52 Week Low | $ | |||
| Day High | $0.74 | P/E | N/A | |||
| Day Low | $0.69 | EPS | $ | |||
| Volume | 2,551,533 | |||||
